(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
10 October 2013 (10.10.2013)

WIPO | PCT

(10) International Publication Number
WO 2013/150309 A8

(51) International Patent Classification:
A61K 39/08 (2006.01) *C07K 14/33* (2006.01)

(21) International Application Number:
PCT/GB2013/050886

(22) International Filing Date:
4 April 2013 (04.04.2013)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
1206070.3 4 April 2012 (04.04.2012) GB

(71) Applicant: **THE SECRETARY OF STATE FOR HEALTH** [GB/GB]; Richmond House, 79 Whitehall, London SW1A 2NS (GB).

(72) Inventors: **SHONE, Clifford**; c/o Public Health England, Porton Down, Salisbury, Wiltshire SP4 0JG (GB). **ROBERTS, April**; c/o Public Health England, Porton Down, Salisbury, Wiltshire SP4 0JG (GB). **MAYNARD-SMITH, Michael**; c/o Public Health England, Porton Down, Salisbury, Wiltshire SP4 0JG (GB).

(74) Agent: **MACLEAN, Martin**; Mathys & Squire LLP, The Shard, 32 London Bridge Street, London SE1 9SG (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:


— *with international search report (Art. 21(3))*

(48) Date of publication of this corrected version:
24 December 2014

(15) Information about Correction:
see Notice of 24 December 2014

(54) Title: CLOSTRIDIUM DIFFICILE ANTIGENS

Figure 1 - illustrates the structures of *C. difficile* Toxins A and B showing amino acid residues at the various domain boundaries.



(57) Abstract: The present invention relates to recombinant Clostridium difficile antigens based on a polypeptide, consisting of or comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence consisting of residues 1500-700 of a C. difficile Toxin A sequence or a C. difficile Toxin B sequence; though with the proviso that the polypeptide does not include one or more Repeat Unit (RU) located between amino acid residues 1851-2710 of C. difficile Toxin A and/ or residues 1853-2366 of a C. difficile Toxin B protein that consists of or comprises a first amino acid sequence and a second amino acid. Also provided is the use of said antigens for the prevention/ treatment/ suppression of Clostridium difficile infection (CDI), together with methods for generating said antigens, methods for generating antibodies that bind to said antigens, and the use of said antibodies for the prevention/ treatment/ suppression of CDI.

WO 2013/150309 A8